tiprankstipranks
Advertisement
Advertisement

VKTX Stock Latest News

Analyst Reiterates Buy on Viking Therapeutics, Citing Best-in-Class Obesity Pipeline and Multiple Value-Creation Catalysts
RatingsAnalyst Reiterates Buy on Viking Therapeutics, Citing Best-in-Class Obesity Pipeline and Multiple Value-Creation Catalysts
4d ago
VKTX
Dick’s Sporting upgraded, Trade Desk initiated: Wall Street’s top analyst calls
PremiumThe Fly
Dick’s Sporting upgraded, Trade Desk initiated: Wall Street’s top analyst calls
9d ago
A
D
Viking Therapeutics initiated with a Buy at Lake Street
PremiumThe Fly
Viking Therapeutics initiated with a Buy at Lake Street
9d ago
VKTX
Viking Therapeutics assumed with a Buy at Truist
PremiumThe Fly
Viking Therapeutics assumed with a Buy at Truist
10d ago
VKTX
Viking Therapeutics Shareholders Back Board, Pay, and Auditor
PremiumCompany Announcements
Viking Therapeutics Shareholders Back Board, Pay, and Auditor
11d ago
8K
VKTX
Viking Therapeutics’ VK2735 demonstrates wieght loss in Phase 2 trial
PremiumThe FlyViking Therapeutics’ VK2735 demonstrates wieght loss in Phase 2 trial
25d ago
VKTX
Viking Therapeutics call volume above normal and directionally bullish
Premium
The Fly
Viking Therapeutics call volume above normal and directionally bullish
1M ago
VKTX
Nash Maintains Buy on Viking Therapeutics, Keeps $107 Price Target Unchanged Amid Strong Cash Runway and Expanded VK2735 Study
Premium
Ratings
Nash Maintains Buy on Viking Therapeutics, Keeps $107 Price Target Unchanged Amid Strong Cash Runway and Expanded VK2735 Study
1M ago
VKTX
Viking Therapeutics price target lowered to $100 from $105 at Cantor Fitzgerald
PremiumThe Fly
Viking Therapeutics price target lowered to $100 from $105 at Cantor Fitzgerald
1M ago
VKTX
Viking Therapeutics price target lowered to $95 from $99 at Morgan Stanley
PremiumThe Fly
Viking Therapeutics price target lowered to $95 from $99 at Morgan Stanley
1M ago
VKTX
Viking Therapeutics Maintained at Buy as VK2735 Advances Through Phase 3, Price Target Reaffirmed at $102
PremiumRatings
Viking Therapeutics Maintained at Buy as VK2735 Advances Through Phase 3, Price Target Reaffirmed at $102
1M ago
VKTX
Viking Therapeutics reports Q1 EPS ($1.37), consensus (91c)
PremiumThe Fly
Viking Therapeutics reports Q1 EPS ($1.37), consensus (91c)
1M ago
VKTX
Viking Therapeutics options imply 7.0% move in share price post-earnings
PremiumThe FlyViking Therapeutics options imply 7.0% move in share price post-earnings
1M ago
VKTX
VKTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
VKTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
1M ago
VKTX
Viking Therapeutics call volume above normal and directionally bullish
Premium
The Fly
Viking Therapeutics call volume above normal and directionally bullish
2M ago
VKTX
3 Best Stocks Under $50 to Buy in April 2026, According to Analysts
PremiumMarket News
3 Best Stocks Under $50 to Buy in April 2026, According to Analysts
2M ago
FIGR
ONON
Viking Therapeutics: Accelerated VK2735 Obesity Program and Single‑Molecule Strategy Support Buy Rating and Favorable Risk‑Reward
PremiumRatings
Viking Therapeutics: Accelerated VK2735 Obesity Program and Single‑Molecule Strategy Support Buy Rating and Favorable Risk‑Reward
2M ago
VKTX
Strong Enrollment and Phase 3 Momentum Underpin Buy Rating on Viking Therapeutics’ Obesity Program
PremiumRatings
Strong Enrollment and Phase 3 Momentum Underpin Buy Rating on Viking Therapeutics’ Obesity Program
2M ago
VKTX
Viking Therapeutics completes enrollment in Phase 3 VANQUISH-2 trial of VK2735
PremiumThe Fly
Viking Therapeutics completes enrollment in Phase 3 VANQUISH-2 trial of VK2735
2M ago
VKTX
T-Mobile, AppLovin, ConocoPhillips, Viking, Western Digital Insider Shake-Up
PremiumWeekend UpdatesT-Mobile, AppLovin, ConocoPhillips, Viking, Western Digital Insider Shake-Up
3M ago
APP
COP
Viking Therapeutics management to meet with Truist
Premium
The Fly
Viking Therapeutics management to meet with Truist
3M ago
VKTX
Maintained Buy Rating on Viking Therapeutics Reflects Confidence in Pipeline Strength and Favorable Risk‑Reward Profile
Premium
Ratings
Maintained Buy Rating on Viking Therapeutics Reflects Confidence in Pipeline Strength and Favorable Risk‑Reward Profile
3M ago
VKTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >